Drug intelligence / Profile preview

[77Br]Br-DAPI

Development stage
Preclinical
Lead developer
Hamamatsu University School of Medicine
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

[77Br]Br-DAPI is a novel, nanoparticle-encapsulated, bromine-77-labeled derivative of the classic nuclear-staining dye DAPI (4',6-diamidino-2-phenylindole), being developed as a therapeutic radiopharmaceutical for Auger electron nuclear medicine. As an Auger electron emitter, bromine-77 (77Br) delivers high linear energy transfer (LET) radiation over an ultra-short range, making its cytotoxicity highly dependent on precise nuclear localization. While free DAPI has poor membrane permeability in live cells, encapsulating [77Br]Br-DAPI within nanoparticles via a pH gradient loading method significantly enhances its intracellular and nuclear delivery. Once inside the nucleus, the DAPI moiety binds strongly to the minor groove of double-stranded DNA, positioning the 77Br isotope in close proximity to the host genome to induce lethal double-strand DNA breaks. Preclinical studies in cancer cell lines have demonstrated that the nanoparticle formulation of [77Br]Br-DAPI dramatically increases cellular uptake and suppresses cell proliferation, highlighting its potential as a targeted radionuclide therapy for cancer.

Other names
77Br-Br-DAPI[77Br]bromodiamidino-phenylindolebromine-77-labeled Br-DAPIbromine77-labeled Br-DAPIbromine 77-labeled Br-DAPIbromine-77-labeled bromodiamidino-phenylindolebromine77-labeled bromodiamidino-phenylindolebromine 77-labeled bromodiamidino-phenylindole
02

Identity

Drug type
Radiopharmaceuticals
Modality
Small MoleculesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesNanoparticles
03

Pharmacology

Targets

Route
Intravenous
04

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

05

Companies

  • Hamamatsu University School of MedicineLead developer
06

Competitive landscape

Drugs on the same target
280

Most advanced

  1. amifostineApproved
  2. bendamustineApproved
  3. bleomycinApproved
  4. bleomycin A2Approved
  5. busulfanApproved

Beyond the preview

Go deeper on [77Br]Br-DAPI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [77Br]Br-DAPI.

Work on [77Br]Br-DAPI? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call